LifeVantage (NASDAQ:LFVN) Releases FY 2025 Earnings Guidance

LifeVantage (NASDAQ:LFVN) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.700-0.800 for the period, compared to the consensus EPS estimate of 0.700. The company issued revenue guidance of $200.0 million-$210.0 million, compared to the consensus revenue estimate of $205.8 million.

LifeVantage Stock Up 0.7 %

Shares of LFVN stock traded up $0.06 during mid-day trading on Wednesday, reaching $8.81. 57,138 shares of the company’s stock traded hands, compared to its average volume of 46,490. The company’s 50-day moving average price is $7.22 and its 200-day moving average price is $6.94. The company has a market cap of $111.90 million, a P/E ratio of 31.46 and a beta of 0.81. LifeVantage has a 12 month low of $4.20 and a 12 month high of $8.99.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.